Literature DB >> 33345731

On the role of the cellular prion protein in the uptake and signaling of pathological aggregates in neurodegenerative diseases.

Giuseppe Legname1, Carlo Scialò1.   

Abstract

Neurodegenerative disorders are associated with intra- or extra-cellular deposition of aggregates of misfolded insoluble proteins. These deposits composed of tau, amyloid-β or α-synuclein spread from cell to cell, in a prion-like manner. Novel evidence suggests that the circulating soluble oligomeric species of these misfolded proteins could play a major role in pathology, while insoluble aggregates would represent their protective less toxic counterparts. Recent convincing data support the proposition that the cellular prion protein, PrPC, act as a toxicity-inducing receptor for amyloid-β oligomers. As a consequence, several studies focused their investigations to the role played by PrPC in binding other protein aggregates, such as tau and α-synuclein, for its possible common role in mediating toxic signalling. The biological relevance of PrPC as key ligand and potential mediator of toxicity for multiple proteinaceous aggregated species, prions or PrPSc included, could lead to relevant therapeutic implications. Here we describe the structure of PrPC and the proposed interplay with its pathological counterpart PrPSc and then we recapitulate the most recent findings regarding the role of PrPC in the interaction with aggregated forms of other neurodegeneration-associated proteins.

Entities:  

Keywords:  Prion protein; neurotoxicity; oligomers; receptor

Year:  2020        PMID: 33345731      PMCID: PMC7757855          DOI: 10.1080/19336896.2020.1854034

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  133 in total

1.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

2.  Stress-protective signalling of prion protein is corrupted by scrapie prions.

Authors:  Angelika S Rambold; Veronika Müller; Uri Ron; Nir Ben-Tal; Konstanze F Winklhofer; Jörg Tatzelt
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

3.  Prion protein "gamma-cleavage": characterizing a novel endoproteolytic processing event.

Authors:  Victoria Lewis; Vanessa A Johanssen; Peter J Crouch; Genevieve M Klug; Nigel M Hooper; Steven J Collins
Journal:  Cell Mol Life Sci       Date:  2015-08-23       Impact factor: 9.261

4.  Gerstmann-Sträussler-Scheinker disease with the Q217R mutation mimicking frontotemporal dementia.

Authors:  John Woulfe; Andrew Kertesz; Inge Frohn; Sharon Bauer; Peter St George-Hyslop; Catherine Bergeron
Journal:  Acta Neuropathol       Date:  2005-07-16       Impact factor: 17.088

Review 5.  Familial Gerstmann-Sträussler-Scheinker disease with neurofibrillary tangles.

Authors:  B Ghetti; F Tagliavini; G Giaccone; O Bugiani; B Frangione; M R Farlow; S R Dlouhy
Journal:  Mol Neurobiol       Date:  1994-02       Impact factor: 5.590

6.  Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia.

Authors:  Changyoun Kim; Dong-Hwan Ho; Ji-Eun Suk; Sungyong You; Sarah Michael; Junghee Kang; Sung Joong Lee; Eliezer Masliah; Daehee Hwang; He-Jin Lee; Seung-Jae Lee
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

7.  The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.

Authors:  Megan Larson; Mathew A Sherman; Fatou Amar; Mario Nuvolone; Julie A Schneider; David A Bennett; Adriano Aguzzi; Sylvain E Lesné
Journal:  J Neurosci       Date:  2012-11-21       Impact factor: 6.167

Review 8.  Biology and genetics of prions causing neurodegeneration.

Authors:  Stanley B Prusiner
Journal:  Annu Rev Genet       Date:  2013       Impact factor: 16.830

9.  Involvement of Cellular Prion Protein in α-Synuclein Transport in Neurons.

Authors:  Laura Urrea; Miriam Segura-Feliu; Masami Masuda-Suzukake; Arnau Hervera; Lucas Pedraz; José Manuel García Aznar; Miquel Vila; Josep Samitier; Eduard Torrents; Isidro Ferrer; Rosalina Gavín; Masato Hagesawa; José Antonio Del Río
Journal:  Mol Neurobiol       Date:  2017-02-22       Impact factor: 5.590

Review 10.  Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome.

Authors:  Benjamin Lam; Mario Masellis; Morris Freedman; Donald T Stuss; Sandra E Black
Journal:  Alzheimers Res Ther       Date:  2013-01-09       Impact factor: 6.982

View more
  4 in total

Review 1.  Anchorless risk or released benefit? An updated view on the ADAM10-mediated shedding of the prion protein.

Authors:  Behnam Mohammadi; Feizhi Song; Andreu Matamoros-Angles; Mohsin Shafiq; Markus Damme; Berta Puig; Markus Glatzel; Hermann Clemens Altmeppen
Journal:  Cell Tissue Res       Date:  2022-01-27       Impact factor: 5.249

2.  Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development.

Authors:  Emily Dexter; Qingzhong Kong
Journal:  Expert Rev Neurother       Date:  2021-09-02       Impact factor: 4.287

Review 3.  Prion Protein: The Molecule of Many Forms and Faces.

Authors:  Valerija Kovač; Vladka Čurin Šerbec
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

Review 4.  Oligomeropathies, inflammation and prion protein binding.

Authors:  Gianluigi Forloni; Pietro La Vitola; Claudia Balducci
Journal:  Front Neurosci       Date:  2022-08-23       Impact factor: 5.152

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.